Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMEN-1: 177Lu-DOTATATE for Recurrent Meningioma
NCT06326190Phase 2Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2025
- Primary completion
- Apr 2027
- Modality
- Peptides, Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in meningioma, sponsored by European Organisation for Research and Treatment of Cancer. Started Mar 2025; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT06326190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326190.